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Transcriptome-wide analysis of 
natural antisense transcripts shows 
their potential role in breast cancer
Stephane Wenric  1,2, Sonia ElGuendi1, Jean-Hubert Caberg3, Warda Bezzaou1,  
Corinne Fasquelle1, Benoit Charloteaux4, Latifa Karim4, Benoit Hennuy4, Pierre Frères2,  
Joëlle Collignon2, Meriem Boukerroucha2, Hélène Schroeder2, Fabrice Olivier2,  
Véronique Jossa5, Guy Jerusalem2, Claire Josse  1,2 & Vincent Bours1,3
Non-coding RNAs (ncRNA) represent 1/5 of the mammalian transcript number, and 90% of the genome 
length is transcribed. Many ncRNAs play a role in cancer. Among them, non-coding natural antisense 
transcripts (ncNAT) are RNA sequences that are complementary and overlapping to those of either 
protein-coding (PCT) or non-coding transcripts. Several ncNATs were described as regulating protein 
coding gene expression on the same loci, and they are expected to act more frequently in cis compared 
to other ncRNAs that commonly function in trans. In this work, 22 breast cancers expressing estrogen 
receptors and their paired adjacent non-malignant tissues were analyzed by strand-specific RNA 
sequencing. To highlight ncNATs potentially playing a role in protein coding gene regulations that occur 
in breast cancer, three different data analysis methods were used: differential expression analysis of 
ncNATs between tumor and non-malignant tissues, differential correlation analysis of paired ncNAT/
PCT between tumor and non-malignant tissues, and ncNAT/PCT read count ratio variation between 
tumor and non-malignant tissues. Each of these methods yielded lists of ncNAT/PCT pairs that were 
enriched in survival-associated genes. This work highlights ncNAT lists that display potential to affect 
the expression of protein-coding genes involved in breast cancer pathology.
Over the past decade, RNA sequencing technology has enabled the determination that the non-coding part of 
the genome represents approximately 1/5 of the transcript number1,2. These non-coding RNAs (ncRNA) are less 
conserved between species than protein coding genes, but more conserved than introns and random intergenic 
regions3,4. It is therefore likely that these non-coding transcripts have biological roles that are progressively being 
deciphered, but still remain largely unknown. NATs are pairs of complementary RNA transcripts originating from 
the same genomic locus (cis-NAT) or an unlinked genomic locus (trans-NAT)5. Among cis-NATs, approximately 
30–50% of the protein coding gene loci additionally express ncRNA in the opposite direction from the protein 
coding gene4,5. This work will focus on this particular subgroup of cis non-coding NATs for the reasons presented 
below.
NATs are less studied than other classes of RNA because their detection and quantification require the preser-
vation of information about the transcript-originating strand along with the sequencing process. Standard RNA 
sequencing requires double-stranded cDNA synthesis, which erases RNA strand information, leading to expres-
sion quantification that is the sum of the expression of both transcripts of the cis-NAT pair. Commercial kits that 
can gather this information have been available for about five years and facilitate new research in the antisense 
transcription field, which is the subject of the present study.
NAT expression is regulated by inducible promoters and enhancers as other genes, but ncNATs accumulate 
preferentially in the nucleus - associated with chromatin - unlike mature coding mRNAs which are located in the 
cytoplasm6–8. NATs are also found in other cellular compartments such as mitochondria or polysomes7–9. ncNAT 
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expression is described in many specific examples to affect in cis the expression of their sense or neighboring 
coding genes in biological events such as cell differentiation and carcinogenesis, with distinct molecular mecha-
nisms being involved8,10–12. ncNATs can regulate gene expression in trans or in cis. Given that both the sense and 
antisense transcripts may be transcribed from the same genomic region, it is expected that antisense transcripts 
behave more frequently in cis than other ncRNAs that commonly function in trans8. The fact that ncNATs may 
regulate their protein coding gene counterpart at the same locus is of great interest from the therapeutic point of 
view: ncNATs may thus provide a unique entry point for therapeutic intervention on targeted genes by the use of 
ASO (antisense oligonucleotides) that are drugs already FDA-approved for several diseases10,13–16.
To date, a few studies have been performed at the whole transcriptome scale to investigate the role of ncNATs 
in the context of breast cancers. These studies have demonstrated that pairs of ncNAT/PCT are globally deregu-
lated in this pathology16–19. However, none of those studies compared the whole transcriptome of paired tumor-
ous and non-malignant tissues of the same patients, with a technology that keeps the strand information of the 
transcripts. Yet, such an experimental design would be needed to explore if ncNAT tumor deregulations are 
cancer-specific, in order to better understand the role of ncNATs in the pathology. Here, we describe the results 
of such an experimental design, in a cohort of 22 ER+ breast cancer patients whose paired non-malignant and 
tumorous tissues were analyzed by stranded RNA sequencing.
This work describes co-expression patterns of ncNATs and their protein coding gene counterparts on the 
same locus, states the disruptions of these patterns observed in the breast cancer pathology and quantifies to 
what extent this phenomenon is occurring. We first defined 3 lists of ncNAT/PCT pairs that are both dereg-
ulated between adjacent non-malignant/tumorous tissues and probably related to ncNATs regulations. Next, 
we demonstrated that those lists are enriched with survival-associated genes. Finally, we established a list of 
breast cancer-related genes potentially regulated by their ncNATs that could be targeted by ASO in a therapeutic 
objective.
Results
The role played by ncNATs on the expression regulation of their corresponding coding transcripts is still largely 
unknown, and this potential regulation could play a role in intermediate- and high-grade ER+ breast cancer 
pathology. Our study experimental design used to answer this question at the transcriptome scale is depicted 
in Fig. 1. Twenty-two tumorous tissues of ER+ breast cancer patients and their paired adjacent non-malignant 
tissues were subjected to strand-specific RNA sequencings and DNA copy number analysis by CGH array. 
The patient characteristics are summarized in Table 1. The cohort contains only tumors larger than 20 mm 
and is equally divided between luminal A and B sub-types and between highly (Ki67 > 19%) and moderately 
(Ki67 < 19%) proliferating tumors. Most present a Bloom grade of 2 and 3.
RNA-Seq Validation. Comparison of RNA transcript expression levels between tumor and adjacent 
non-malignant tissues were combined with the corresponding DNA copy number variations: the overall expres-
sion levels of coding gene transcripts inside genomic amplifications or deletions that were newly acquired in the 
tumor were respectively increased and decreased, as expected (Supplemental File 1/Fig S1A).
Moreover, gene expression changes between non-malignant and tumor tissues obtained in our RNA-Seq 
dataset were compared to those obtained in an independent microarray dataset (GSE65216). Gene expression 
variation between 10 mammary normal tissues and 22 ER+ tumors (11 luminal A and 11 luminal B) were 
extracted using Geo2R20. The gene expression fold-changes that were differentially expressed with an adjusted 
p-value < 0.05 between non-malignant and tumor tissues in both our and the GSE65216 datasets were com-
pared and presented an average Spearman correlation coefficient of 0.613 (p-value < 0.001), with 76.6% of 
these genes differentially modulated in the same direction (Supplemental File 1/Fig S1B). GSEA analysis using 
the GenePattern tool was also conducted to compare the respective gene sets enrichment in the tumor tissues 
of our RNAseq and the GSE65216 microarray datasets. A total of 1026 gene sets were found to be enriched 
in the RNASeq dataset. Among them, 870 were also enriched in the GSE65216 microarray dataset, showing 
an 85% homology in gene set enrichment. The 100 first enriched gene sets in tumor tissues were listed in the 
Supplemental file S1/Table S2. In addition, enrichment plots of several representative pathways that are differ-
entially enriched in tumor and non-malignant adjacent tissues are presented in Supplemental File 1/Figure S3, 
showing comparable profiles in our RNASeq dataset and the GSE65216 microarray dataset (http://genepattern.
broadinstitute.org/gp/)21.
At a smaller scale, RT-qPCR experiments were performed on RNA samples that were used for our RNA-Seq 
study to confirm variations in the expression of several transcripts between tumor and non-malignant tissues. 
Seventy percent of the tested transcripts showed consistent variations as measured by the two techniques. 
Downregulation in the tumors of the ADAMTS9 tumor suppressor and its ncNAT, ADAMTS9-AS2 are presented 
in Supplemental File 1/Fig S1C as representative results.
ncNAT expression accounts for 17% of the coding counterpart in non-malignant adjacent tis-
sues and increases to 26% in tumors. We next defined pairs of protein-coding genes and their corre-
sponding antisenses, as detailed in the material and methods section. This list can be found in Supplemental 
File 2/Table 1 and contains 9632 ncNAT/PCT pairs where at least one patient has a non-null expression for 
PCT or ncNAT, either in the non-malignant adjacent tissue or in the tumor. As 19846 coding transcripts were 
expressed in mammary tissues, 49% of coding transcripts have a concomitant corresponding ncNAT expression. 
Globally, ncNAT read counts represent 17% of their coding counterparts in non-malignant tissues and 26% in 
tumors (Table 2), suggesting a global increase in the expression levels of ncNATs in mammary tumors. Moreover, 
the average read counts ratio between PCT/ncNAT transcript pairs expressed simultaneously by a locus is 1544 
in adjacent non-malignant tissues and 1013 in tumors (Supplemental File 2/Table 1).
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The 9632 PCT/ncNAT transcript pairs contain 6494 unique protein-coding genes and 8861 unique ncNATs 
genes. Forty percent of the PCT/ncNAT transcript pairs (3888) display a unique transcript on the opposite strand, 
while the other pairs overlap with two to nine transcripts. The detailed overlap between PCT and ncNAT tran-
scripts is described in the Supplemental File 1/Table S4.
The reads count distributions of the four transcript types among the 9632 ncNAT/PCT pairs are represented 
in Fig. 2A. The ncNAT distributions are clearly different in non-malignant and tumor tissues (Mann-Whitney 
Wilcoxon pval = 2.2E-16 in ALL genomic variation status; pval = 0.145 in AMP; pval = 0.0022 in DEL; 
pval = 2.2E-16 in NEUTRAL), with a higher number of ncNATs displaying reduced expression in the tumors 
(yellow surface at the left of red peak) compared to the number of ncNATs that are increased in the tumors (yel-
low surface at the right of the red peak). The genomic amplifications and deletions affect the ncNAT transcripts 
distributions less than the cancerous or non-malignant status of the tissue (comparing the AMP or DEL distribu-
tion to the NEUTRAL distribution). Indeed, genomic alterations are relatively occasional in ER+ breast cancers.
Based on the levels of expression in the different tissue types, we chose to focus on ncNAT/PCT pairs 
where both the PCT and NAT were expressed in at least seven of the 22 patients, both in the tumor and the 
non-malignant tissue. This represents more than 60% of the total read counts of ncNAT/PCT pairs (Table 2). 
Figure 1. Study workflow. RNA and DNA were simultaneously extracted from 23 breast cancer ER+/HER2− 
tumors and their paired adjacent non-malignant tissues. Strand-specific paired-end RNA sequencing and 
comparative genomic hybridization (CGH) were performed. Quality control steps and RNA-Seq validation 
were performed and led to the elimination of one patient due to poor strand specificity in this sample. This 
strategy allowed the study of the differential expression of ncNATs and PCTs between tumors and non-
malignant tissues and performance of differential correlation analysis of ncNAT/PCT pairs. Three lists of genes 
with deregulated ncNAT expression in tumors that could potentially affect the corresponding PC expression 
were extracted, and their coding genes were subjected to survival analysis with an external cohort (TCGA).
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This choice was made because the next gene analysis is mainly based on transcript expression correlations and 
expression ratios. A total of 4748 ncNAT/PCT pairs present low expression in at least one of the four catego-
ries compared (PCT tumor, PCT non-malignant, ncNAT tumor, ncNAT non-malignant), leading to aberrant 





>20 N = 22
<20 N = 0
Ki 67 (%)
<19 N = 11
≥19 N = 10
Unknown N = 1
Histology
IDC + DCIS N = 7
IDC N = 15
Bloom grade
I N = 4
II N = 9
III N = 9
T (x to 4)
1c N = 10
2 N = 11
3 N = 1
N (x to 3)
0 N = 13
1a N = 5
1c N = 1
2a N = 2
3a N = 1
M (0 or 1)
0 N = 22
1 N = 0
Molecular subtype
ER + /HER2- N = 22
Luminal A N = 11
Luminal B N = 11
Meantime follow-up Month 43.36
Table 1. Patient clinicopathological characteristics.
Nber NAT/
PC pairs
transcript non-null expression in more than 7/22 patients sum of read counts
PC norm tissue PC tum NAT norm tissue NAT tum PC norm tissue PC tum NAT norm tissue NAT tum
4884 yes yes yes yes 5.56E + 07 4.73E + 07 1.73E + 07 2.26E + 07
3282 yes yes no no 3.51E + 07 2.89E + 07 1.62E + 04 2.49E + 04
944 yes yes no yes 1.08E + 07 1.02E + 07 1.03E + 04 2.12E + 04
149 yes yes yes no 2.06E + 06 1.17E + 06 2.61E + 03 2.06E + 03
149 no no yes yes 4.81E + 02 9.21E + 02 7.11E + 04 6.73E + 04
89 no no no no 2.51E + 02 3.85E + 02 5.65E + 02 8.20E + 02
50 no yes yes yes 9.32E + 02 1.77E + 03 2.27E + 04 4.29E + 04
29 no yes no no 5.16E + 02 9.14E + 02 1.35E + 02 2.42E + 02
28 no no no yes 9.85E + 01 1.64E + 02 3.23E + 02 5.69E + 02
11 yes no yes yes 2.42E + 02 2.38E + 02 2.02E + 03 2.32E + 03
7 no yes no yes 9.24E + 01 1.93E + 02 9.25E + 01 1.88E + 02
5 yes no no no 1.50E + 02 1.43E + 02 1.61E + 01 3.80E + 01
3 no no yes no 3.26E + 01 2.27E + 01 4.59E + 01 8.58E + 01
1 yes no yes no 5.67E + 01 1.53E + 01 1.00E + 01 1.48E + 01
1 no yes yes no 4.84E + 00 8.32E + 00 1.53E + 01 2.86E + 01
0 yes no no yes 0.00E + 00 0.00E + 00 0.00E + 00 0.00E + 00
Total 9632 NAT/PCT pairs where at least one patient has a non-null expression in one of those four transcript types
1.04E + 08 8.75E + 07 1.74E + 07 2.28E + 07
2.31E + 08
Table 2. Distribution of the relative expression intensities of ncNATs and their corresponding PCTs among the 
9632 ncNAT/PCT pairs. This study was focused on ncNAT/PCT pairs where both the PCTs and the NATs were 
expressed in at least 7 out of the 22 patients, both in the tumor and the non-malignant tissue. This group of 4884 
gene pairs contains 60% of the total reads counts, and the ncNAT/PCT ratio expression is increased in tumors.
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Figure 2. (A). ncNAT and PCT transcript distributions in adjacent non-malignant healthy tissue and tumors. 
Density plot of log10 (mean counts) of the four transcript types (ncNAT tumor; ncNAT non-malignant, PCT 
tumor, PCT non-malignant). The upper panel contains the complete list of 9632 ncNAT/PCT pairs; the second 
panel contains ncNAT/PCT pairs in amplified genomic regions; the third panel contains ncNAT/PCT pairs 
in deleted genomic regions; and the last panel contains ncNAT/PCT pairs in copy-number-neutral genomic 
regions. The ncNAT distributions are clearly different in non-malignant and tumor tissues, with a higher 
number of ncNATs displaying reduced expression in the tumors than the number of ncNATs that are increased 
in the tumors. (B) Presents the same information as panel A, but in the highly expressed ncNAT subgroup 
of the 4882 ncNAT/PCT pairs. (C) Schematic representation of proportion of different classes of differential 
correlations between tumors and non-malignant tissues. Primarily positive correlations of expression between 
ncNAT and their corresponding PCT are created or lost in tumorous tissues. The numbers indicated in the 
graph are the number of ncNAT/PCT pairs in this category; +/+= significant positive correlation between 
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Spearman correlation values or an invalid expression ratio. To avoid this pitfall, we only kept ncNAT/PCT pairs 
with at least seven non-null values in the four categories, corresponding to one third of the patient cohort. This 
choice ensures that the statistical tests are accurate and restricts the finding to recurrent observations, which are 
more interesting from medical and therapeutic standpoints. In this group of 4884 transcript pairs, the number 
of tumor ncNAT read counts increased compared to the adjacent non-malignant tissues (Table 2). Moreover, the 
ncNAT/PCT ratio of 31% in adjacent non-malignant tissues is increased to 47.8% in tumors. The broken balance 
of expression between ncNAT and PCT observed in the tumor could increase the probability of the occurrence 
of deregulated mechanisms, and hence this gene sub-group could contain PC transcripts that display a stronger 
potential for regulation by their ncNAT counterparts.
The discordant ncNAT/PCT pairs can occur either due to variations in ncNAT transcript expression between 
tumors and non-malignant tissues, or PCT variations, or variations in both. To determine which case is more 
frequently observed in the 4884 ncNAT/PCT pairs, the mean counts of the four categories of transcripts (PCT 
tumor, PCT non-malignant, ncNAT tumor, ncNAT non-malignant) for the ncNAT/PCT pairs in the 22-patient 
cohort were plotted (Fig. 2B). The results show that ncNAT was expressed approximately 1000-fold less than 
PCT. The distribution of PCT read counts is quite comparable in the tumor and adjacent non-malignant tis-
sue. However, ncNAT read counts appeared to be slightly increased in the tumors compared to the adjacent 
non-malignant tissues (shift of the curve to the right). This suggests that the discordant ncNAT/PCT pairs mainly 
occur via modifications of the ncNAT expression in the tumors.
Positive correlations of expression between ncNAT and corresponding PCT are created in 
tumorous tissues. To highlight newly appearing or disappearing correlations between ncNATs and their 
corresponding PCTs in tumors, differential correlation analysis between all pairs of PCTs and ncNATs was per-
formed using DGCA software (v. 1.0.1)22. Complete results can be found in Supplemental File 2 / Table 1, showing 
a global positive correlation of expression between ncNATs and their corresponding PCTs: the mean Spearman 
correlation coefficients were 0.431 and 0.533, respectively, in non-malignant tissues and tumors when a signif-
icant correlation was observed (p-value < 0.05), namely, in 20% of the 4884 ncNAT/PCT pairs. The number of 
significantly correlated ncNAT/PCT pairs does not differ in non-malignant and tumorous tissues. A positive 
mean z-score (0.460) is observed in the case of a significant differential correlation of ncNAT/PCT between tumor 
and non-malignant tissues (p-value < 0.05), meaning that globally, in the 11% of ncNAT/PCT pair correlations 
that are deregulated in tumors compared to non-malignant tissues (567/4884 pairs), the correlations become 
more positive. The proportion of different classes of differential correlations between tumors and non-malignant 
tissues is depicted in Fig. 2C, highlighting the fact that mainly positive correlations of expression between ncNATs 
and their corresponding PCTs are created or lost in tumorous tissues. Very few inversions of correlation were 
observed.
Some examples of ncNAT/PCT pairs demonstrating deregulated correlation of expression in the tumor tissue 
are presented in Table 3, which shows that genes well-known in the breast cancer field display deregulated corre-
lation of expression with their antisense transcripts.
Protein-coding genes exhibiting corresponding deregulated ncNAT expression in tumors are 
preferentially related to survival of breast cancer patients. Three different analytical methods were 
used to select ncNAT/PCT pairs that were potentially related to breast cancer pathology out of the 4884 pairs.
First, the previously described DiffCor is based on the differential correlation of ncNAT/PCT read counts 
between non-malignant and tumor tissues. A list of ncNAT/PCT pairs whose correlation was significantly dif-
ferent between normal and tumor tissues (p-value < 0.05) and whose correlation class differed between tumor 
and normal tissues (i.e., 0/0, +/+, −/− classes are removed) was selected and contained 441 ncNAT/PCT pairs.
The second method is based on the differential expression of ncNATs between tumors and non-malignant tis-
sues. A list of 738 ncNAT/PCT pairs was determined, for which ncNATs were significantly differentially expressed 
(adjusted p-value < 0.05) between normal and tumor tissues.
The third method is based on the variation in the ncNAT/PCT ratio between non-malignant and tumor 
tissues, and allows the definition of a third list, called VarRatio, that contains ncNAT/PCT pairs with extreme 
values in the distribution of the VarRatio (Supplemental File 1/Figure S5). This VarRatio list can be sub-
divided into leftmost and rightmost parts. The leftmost 610 ncNAT/PCT pairs have a PCT/ncNAT ratio 
that decreases in the tumor, either because of a down-regulation in PCT expression, or an up-regulation in 
ncNAT expression, or both; the reverse is observed for the 540 ncNAT/PCT pairs on the rightmost end of 
the distribution.
The three lists of genes can be found in the Supplemental File 1/Tables S6 to S9, and as expected, many ncNAT/
PCT pairs appear in several of these lists, which contain a total of 1784 unique ncNAT/PCT pairs that are dereg-
ulated in breast cancers.
ncNAT and PCT in adjacent non-malignant tissue and conserved in the tumor; +/−= significant positive 
correlation between ncNAT and PCT in the adjacent non-malignant tissue that becomes negative in the tumor; 
+/0= significant positive correlation between ncNAT and PCT in the adjacent non-malignant tissue that is 
lost in the tumor; −/−= significant negative correlation between ncNAT and PCT in adjacent non-malignant 
tissue that is conserved in the tumor; −/+= significant negative correlation between ncNAT and PCT exists 
in adjacent non-malignant tissue that becomes positive in the tumor; −/0= significant negative correlation 
between ncNAT and PCT in the adjacent non-malignant tissue that is lost in the tumor; 0/0 = no significant 
correlation between ncNAT and PCT exists in the adjacent non-malignant tissue or the tumor.
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To ascertain if the protein coding genes in the DiffCor, ncNATDiffExp, and VarRatio lists are implicated 
in breast cancer pathology, their association with survival was computed based on RNA-Seq samples from the 
TCGA dataset. Each of these three lists present a proportion of genes associated with survival in the TCGA data-
set greater than the proportion obtained in a list of randomly chosen protein coding genes (Table 4). This means 
that PCT exhibiting corresponding deregulated ncNAT expression in tumors are enriched in genes related to the 
survival of breast cancer patients. A Pearson’s chi-squared test yielded statistically significant p-values for each of 
the three lists compared to both control lists.
Analyses were conducted to explore the relationship of the protein coding genes of DiffCor, ncNATDiff-
Exp, and VarRatio lists to known prognostic factors, but no significant results were found (Supplemental File 1/
Table S10). In the same way, enrichment analyses in pathways genes were conducted, without any noticeable 
results. The proportion of various different ncNAT biotypes in the (i) DiffCor classes of ncNAT/PCT pairs, and 
(ii) the DiffCor, ncNATDiffExp, and VarRatio lists were calculated and did not show any statistically significant 
differences. The mean p-value of ncNAT/PCT expression correlation in tumors and adjacent non-malignant 





























ACSL6 ENSG00000234758 AC034228.4 −0.353 1.07E-01 0.441 4.01E-02 2.59 9.48E-03 0/+
AFF1 ENSG00000235043 TECRP1 0.762 3.74E-05 0.247 2.69E-01 −2.31 2.08E-02 +/0
BRCA1 ENSG00000240828 RPL21P4 0.625 1.87E-03 −0.041 8.57E-01 −2.39 1.70E-02  + /0
CAMTA1 ENSG00000225126 RP4-549F15.1 −0.093 6.82E-01 0.698 3.06E-04 2.95 3.22E-03 0/+
CAMTA1 ENSG00000269978 RP11-338N10.3 0.817 3.41E-06 0.139 5.36E-01 −3.11 1.87E-03 +/0
CDKN2B ENSG00000240498 CDKN2B-AS1 −0.541 9.31E-03 0.269 2.27E-01 2.72 6.61E-03 −/0
CEBPA ENSG00000267727 CTD-2540B15.7 0.788 1.31E-05 −0.013 9.55E-01 −3.33 8.74E-04 +/0
CTCF ENSG00000237718 AC009095.4 −0.249 2.63E-01 0.577 4.96E-03 2.81 4.93E-03 0/+
GNA11 ENSG00000267139 AC005262.3 −0.135 5.49E-01 0.483 2.28E-02 2.04 4.11E-02 0/+
GNAS ENSG00000235590 GNAS-AS1 −0.599 3.22E-03 0.261 2.41E-01 2.96 3.12E-03 −/0
HLF ENSG00000263096 RP11-515O17.2 −0.494 1.95E-02 0.142 5.29E-01 2.11 3.50E-02 −/0
HNF1A ENSG00000241388 HNF1A-AS1 0.023 9.18E-01 0.668 6.87E-04 2.41 1.58E-02 0/+
HOXC11 ENSG00000228630 HOTAIR 0.078 7.29E-01 0.625 1.87E-03 2.02 4.36E-02 0/+
MAP2K1 ENSG00000269999 CTD-3185P2.2 −0.523 1.26E-02 0.099 6.62E-01 2.09 3.64E-02 −/0
MSH2 ENSG00000236558 AC138655.6 0.762 3.74E-05 0.156 4.88E-01 −2.60 9.26E-03 +/0
MSH6 ENSG00000224058 AC006509.7 0.567 5.89E-03 −0.100 6.58E-01 −2.29 2.18E-02 +/0
MYH11 ENSG00000263065 AF001548.6 0.662 7.94E-04 0.030 8.95E-01 −2.36 1.82E-02 +/0
PPP6C ENSG00000232630 PRPS1P2 −0.187 4.05E-01 0.453 3.41E-02 2.09 3.66E-02 0/+
RAP1GDS1 ENSG00000214559 RP11-323J4.1 0.159 4.78E-01 0.911 3.99E-09 4.23 2.38E-05 0/+
UBR5 ENSG00000246263 KB-431C1.4 0.164 4.65E-01 0.813 4.16E-06 2.99 2.76E-03 0/+
UBR5 ENSG00000272037 KB-431C1.5 0.235 2.91E-01 0.735 9.92E-05 2.15 3.13E-02 0/+
WT1 ENSG00000183242 WT1-AS 0.392 7.09E-02 0.885 4.46E-08 3.03 2.42E-03 0/+
ZFHX3 ENSG00000259901 RP5-991G20.4 −0.322 1.44E-01 0.503 1.71E-02 2.73 6.26E-03 0/+
Table 3. Examples of spearman correlations between ncNAT and cancer-associated coding genes that are 
altered in tumors when compared to adjacent non-malignant tissues.
PC Gene list DiffCor ncNATDiffExp VarRatio Left VarRatio Right
Random protein-coding 
genes with antisense overlap
Random protein-coding genes 
without antisense overlap
Nb genes in list 441 738 610 540 582 582
Nb genes also present in TCGA dataset 440 729 604 533 582 582
Nb genes w/ log-rank p-val <= 0.05 71 118 96 84 57.38 ± 7.32 41.48 ± 6.61
Genes % w/ log-rank p-val <= 0.05 16.1% 16.2% 15.9% 15.8% 13.83 ± 1.78% 12.27 ± 1.91%
Average log-rank p-val 0.392 0.387 0.388 0.391 0.404 ± 0.0315 0.483 ± 0.357
Table 4. PC genes exhibiting deregulated corresponding ncNAT expression in tumor are preferentially related 
to survival of breast cancer patients. Protein coding genes of the 3 gene lists DiffCor, ncNATDiffExp and 
VarRatio (left and right) were tested for association with survival by means of a TCGA RNA-Seq dataset of 
breast cancers. The percentage of genes associated with survival in each list has been compared with 2 control 
distributions containing randomly selected protein coding genes.
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72 cancer genes present a deregulated profile of ncNAT expression in breast cancer samples. 
When the Cancer Gene Census list of genes from the COSMIC database (http://cancer.sanger.ac.uk/census) 
was compared to our three lists of genes that are potentially regulated by their ncNATs and implicated in breast 
cancer pathology, 72 genes were shared (Supplemental File 1/Table S11). This list of 72 genes contains cancer 
genes that could be targeted by ASO and designed to interact with the corresponding ncNATs of those genes to 
specifically regulate their expression.
Discussion
Breast cancer constitutes a public health problem: approximately 1 in 8 women will suffer from breast cancer 
during her lifetime in industrialized countries. The most frequent subtype is estrogen-receptor-expressing breast 
cancer (ER+/HER2−), which accounts for 75% of occurrences23. In primary disease, most patients are treated 
with surgery with or without radiotherapy and endocrine therapy. However, a large number of these patients will 
suffer from a relapse and develop metastases24—a major life-threatening event that is strongly associated with 
poor outcomes—and will require chemotherapy in the case of symptomatic visceral disease25. New therapies are 
thus needed, as are biomarkers that would give a better prediction of the relapse risk24,26. Our study explores the 
still new field of antisense transcription to define potential target gene lists and will lead to further work to define 
predictive markers and/or tailor targeted treatment using antisense oligonucleotides (ASO)15.
This is the first time that a whole transcriptome strand-specific RNA-Seq study focusing on antisense tran-
scription has been performed in paired tumor and adjacent non-malignant mammary tissues. This experimental 
design allows the detection of deregulation of ncNAT expression that occurs in cancer tissues and statistically 
connects them to changes in the corresponding coding transcript expression. A global increase in transcription 
due to sustained cell proliferation is described in cancers, and the observed increased ncNAT expression could 
be attributed to this phenomenon or to impaired antisense transcript degradation. However, as the respective 
proportional rise of ncNAT and PCT in the transcript pairs encoded on the same loci differs in tumors and adja-
cent non-malignant tissues, deregulated mechanisms of gene expression control could arise. In particular, we 
revealed that many positive correlations between ncNATs and their PCT counterparts were appearing or fading 
in the tumor, suggesting newly acquired or lost regulations of protein-coding transcripts in the cancerous tissues. 
Moreover, the association of these ncNATs with survival was evaluated through the use of their protein-coding 
counterparts as a proxy in a large independent cohort. The detected associations suggest that the dysregulation 
observed within the landscape of ncNATs is not merely a random byproduct of the tumoral process. However, 
this work is based on correlation analysis, and does not demonstrate any causative aspect. As a result, further 
functional molecular studies will be needed to confirm the existence of such regulation of PCTs by their ncNATs 
in the list of cancer gene pairs highlighted in this work. Enrichment analyses were conducted to explore the 
lists of ncNAT/PCT pair genes defined in this study, but no noticeable result was obtained. In the same way, no 
enrichment in transcription-factor binding sites was observed, in contrast with a previous report stating that the 
GABPA transcription factor is associated with antisense promoters in breast cancer16.
Several studies have already explored the role of antisense transcription in breast cancer16–19,27. Grinchuk et al. 
analyzed ncNAT/PCT pairs that are deregulated in breast cancer to define the pathways in which they are particu-
larly involved; these researchers defined ncNAT/PCT-based prognosis signatures that were validated in additional 
cohorts. Affymetrix microarray datasets were used to identify the natural antisense gene pairs, but normal breast 
epithelium and mammary tumor tissues analyzed were not matched16. Moreover, Balbin et al. performed a large 
scale, genome wide, stranded RNA-Seq study of 376 cancers samples with 60 primary breast cancers among 
them17. However, as in Grinchuck’s study, tumorous tissues were not matched with non-malignant tissues and 
thus these studies did not explore, patient by patient, whether the ncNAT/PC expression correlations were already 
present in the normal tissue, or whether they were newly acquired in the tumor. Despite the relatively small num-
ber of patients and samples, this particularity in our experimental design did allow us to highlight the fact that 
ncNAT expression is increased in tumorous tissues compared to their coding counterparts. Indeed, the propor-
tion of ncNAT read counts in ncNAT/PCT pairs in ER-positive intermediate- and high-grade estrogen-positive 
breast cancers is globally increased in tumors compared to adjacent non-malignant tissues.
As Balbin et al. have stated before, at any locus where PCT and ncNAT are simultaneously transcribed, PCT 
is expressed approximately 1000-fold more than ncNAT, but we have additionally observed that this difference 
in expression is lower in tumors than in non-malignant tissues. We also found that, globally, 10% of transcripts 
come from the antisense strand in non-malignant tissues and that this proportion is increased to 13% in tumors 
(8% were described by Balbin et al.). However, some patients presented a much higher increase in the ncNAT/
PCT proportion in the tumor than others. This heterogeneity in ncNAT expression deregulation across patients 
could be used to stratify patients into subgroups with different prognoses. One limitation of our study is the 
small size and the short follow-up of our cohort, which did not allow such analysis and weakened the statistical 
power needed to show a potential relationship between ncNAT expression and known prognostic factors, which 
is commonly recommended for biomarker selection. Another biological limitation is that, as NAT expression is 
low, false positive and negative results in the correlation analysis are frequent when applied to the complete 9632 
NAT/PCT pairs list. This issue was circumvented by limiting the analyses to the highly expressed NAT subgroup 
of 4884 NAT/PCT pairs.
Our results confirmed the observation made by Grinchuk et al., who showed that the NAT content in breast 
tumors globally increases and that the expression correlations between ncNAT and PCT were different in tumors 
compared to unrelated non-malignant tissues16,19. We refined this observation using paired tissues from the same 
patient and showed that globally these correlations become more significant and more positive in the tumors. 
Moreover, we highlighted the gene pairs where potential new PCT/ncNAT expression regulation occurs in can-
cerous tissues. After performing a survival analysis with gene expression data from an external cohort (TCGA), 
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it appears that these ncNAT/PCT gene pairs were also enriched in survival-associated genes, suggesting that 
opposite-strand transcription regulation might play a role in breast cancer disease.
Therefore, our report indicates that ncNAT expression is often increased in cancer samples compared to 
matched non-malignant adjacent tissues. The relevance of this observation for coding gene expression, cancer 
biology, prognosis and treatment will need to be determined in large, specific cohorts of paired samples with 
long-term follow-up of the patients.
Material and Methods
Ethical Statement. Tissues were obtained from the Liege University Biobank (N = 12) and the St Vincent 
Clinic of Rocourt (N = 11), Belgium. This study was approved by the local institutional ethical board (“Comité 
d’éthique hospital-facultaire universitaire de Liège (707)) under the file number 2010/229. All aspects of the study 
comply with the Declaration of Helsinki. Patients from Liege University Hospital were recruited on the basis of 
an opt-out methodology. Patients from the St Vincent Clinic of Rocourt were informed of the research work and 
provided with written informed consent.
Patients and samples. This retrospective study was performed on 23 cryopreserved cancerous and adjacent 
non-malignant tissues from 23 women suffering from estrogen receptor-expressing breast cancer. Samples were 
collected from 2010 to 2014. One patient was excluded due to the poor strand-specificity of the RNA-Seq. The 
clinical and pathological parameters of the patients included in the final analysis were recorded and are summa-
rized in Table 1.
A summary of the experimental design is depicted in Fig. 1.
DNA/RNA/miRNA extraction. DNA, RNA and miRNA were simultaneously extracted using an All Prep 
DNA/RNA/miRNA Universal kit (Qiagen, Belgium) according to the manufacturer’s protocol. The RNA quality 
was assessed using a BioAnalyzer (Agilent, Belgium).
TruSeq® Stranded Total RNA by Illumina® and next generation sequencing. RNA sequencing 
libraries for 23 breast tumors and paired adjacent tissues were constructed from 500 ng of total RNA using the 
TruSeq® Stranded Total RNA kit and the Ribo-Zero rRNA Removal kit. A step of chemical fragmentation gener-
ated RNA fragments of 180 pb. This step was adapted according to RNA quality as described in the manufacturer’s 
protocol. The syntheses of the first and second strands of cDNA were performed with random hexamer primers. 
Twelve cycles of PCR were performed to amplify the libraries. The quality and size of the cDNA libraries were 
assessed using Bioanalyzer Agilent Chip DNA 1000. Only libraries from 290 bp to 300 bp were used, and 14 pmol 
final cDNA libraries were loaded on an Illumina HiSeq2000 apparatus for cluster generation and paired-end 
sequencing of 2 × 100 bp, with a mean of 8.26E + 09 bases sequenced for each sample (4 samples/flow cell). Kits 
and apparatus were from Illumina, The Netherlands.
CGH array. Array comparative genomic hybridization was performed in non-malignant and tumorous tissues 
from the 23 patients using the Agilent 60 K microarray platform (G4827A-031746; Agilent Technologies, Santa 
Clara, CA, USA) according to the manufacturer’s instructions. The arrays were scanned with a SureScan High 
Resolution Microarray Scanner (Agilent Technologies, Santa Clara, CA, USA). Data and images were imported 
using Feature Extraction V.9.5.3.1 Software, and results were analyzed with CytoGenomics software v2.5 (Agilent 
Technologies, Santa Clara, CA, USA). The Aberration Detection Methods 2 algorithm (ADM-2) was used with 
a cut-off of 6.0, followed by a filter to select regions with three or more adjacent probes and a minimum average 
log2 ratio ± 0.25, which was used to detect copy number changes. The quality of each experiment was assessed by 
measuring the derivative log ratio spread using CytoGenomics software v2.0. Genomic positions were based on 
the UCSC February 2009 human reference sequence (hg19) (NCBI build 37 reference sequence assembly). Copy 
number changes were filtered using the BENCHlab CNV software (Cartagenia, Leuven, Belgium).
Gene expression quantification by RNA-Sequencing. Quality control for the sequenced reads 
has been performed with FastQC software (v. 0.11.2; https://www.bioinformatics.babraham.ac.uk/projects/
fastqc/). Sequencing reads were mapped to the Human Genome hg19 GRCh37-75 (Ensembl) using Star 
2.4.1c software28. Mapping quality was assessed with the Picard RnaSeqMetrics tool in the Picard software 
suite (v. 1.127; http://broadinstitute.github.io/picard/) using default parameters. The results are available in 
Supplemental File 1/Table S12. Read count assignment was performed with the htseq-count tool of the HTSeq 
software suite (v. 0.6.1)29. Data quality assessment was performed by computing the strand specificity (ratio 
of sequencing reads mapping to incorrect strands) of all samples with htseq-count, leading to the removal of 
one patient who showed aberrant strand specificity. DESeq. 2 software (v. 1.10.1) was used to normalize read 
counts, estimate dispersion, perform variance stabilizing transformation, and perform independent filtering 
using the mean of normalized counts as a filter statistic, thereby adjusting the filtering threshold at 33%, fol-
lowing the standard workflow30. Variance-stabilization performance was assessed by producing MA-plots of 
log2-fold-change versus mean expression using DESeq. 2. Outliers were searched for by computing Cook’s 
distances for every gene and every sample with DESeq. 2 (Supplemental File 1/Figures S13–S17). A prin-
cipal component plot was performed to assess the appropriate separation between the two sample classes 
(Supplemental File 1/Figure S18). All aforementioned quality and performance measures yielded acceptable 
results for all remaining samples.
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Data availability. The raw and processed RNASeq data were submitted to GEO DataSet under the series 
record GSE103001.
Quantitative RT-qPCR. Reverse transcription was performed using the Reverse Aid H Minus kit 
(LifeTechnologies, Belgium) from 100 ng of total RNA using random hexamer primers in the case of coding genes 
and using target-specific primers coupled to an unrelated synthetic DNA oligonucleotide in the case of ncNAT.
Quantitative PCR were performed using specific 6-FAM/ZEN/IBFQ probes (IDT, Belgium) with Kapa Probe 
Fast qPCR Master Mix (Sopachem, Belgium) on a LightCycler 480 apparatus (Roche). In the case of coding gene 
amplification, the primers were designed according to a standard procedure. In the case of ncNAT gene amplifi-
cation, a primer specific to the target ncNAT and a primer specific to the synthetic oligonucleotide added during 
reverse transcription were used to allow strand-specific amplification.
The relative expression was calculated using the standard curves methods, using beta−2-microglobuline as 
endogenous standard.
Primers and probe sequences can be found in the Supplemental File 1/ Additional Materials and Methods.
External dataset used for RNASeq gene expression comparison. Gene expression variations 
were retrieved from the de GEO Dataset GSE65216 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?ac-
c=GSE65216), which is an expression study using the micro-array (Affymetrix) of the Maire’s breast cancer 
cohort31.
Definition of protein-coding/antisense pairs. The list of pairs of protein-coding genes and their corre-
sponding antisense transcripts was generated based on human genome assembly and gene annotation GRCh37 
(release 75) from Ensembl32. To be included in the list, pairs of genes had to fulfill the three following conditions: 
overlapping coordinates; opposite strands; one of the two genes must have a protein_coding biotype, while the 
other can have any of the following biotypes: 3prime_overlapping_ncrna, antisense, IG_C_pseudogene, IG_V_
pseudogene, lincRNA, misc_RNA, polymorphic_pseudogene, processed_transcript, pseudogene, sense_intronic, 
sense_overlapping, snoRNA, snRNA. The reasoning behind including all non-protein_coding biotypes as putative 
antisenses is that the Ensembl annotation of antisense is limited to already validated antisenses and thus might 
miss previously unknown antisenses.
ncNAT/PCT Gene list selection methods. 
 (1) DiffCor list: Differential correlation analysis between pairs of protein-coding and antisense transcripts 
was performed using DGCA software (v. 1.0.1)22. Pairs of protein coding/antisense genes were selected for 
which the correlation significantly differed between normal and tumor samples (adjusted p-value < 0.05) 
and for which correlation class differed between tumor and normal samples (i.e., we removed the 0/0, +/+, 
−/− classes).
 (2) ncNATDiffExp list: Differential expression analysis between all tumor and non-malignant samples was 
performed using DESeq. 2 software (v. 1.10.1) for all genes, following the standard multi-factor workflow 
for paired samples. Pairs of protein coding/antisense genes were selected for which the antisense was sig-
nificantly differentially expressed (adjusted p-value < 0.05) between normal and tumor samples.
 (3) varRatio list: Read count ratio variation analysis was performed as follows: define the variation of read 
counts ratio (varRatio) for each pair of ncNAT/PCT genes as
Equation 1



















Pairs of ncNAT/PCT genes corresponding to extreme values of the varRatio distribution were selected 
by applying a threshold (mean ± standard deviation) to the log-transformed distribution of the varRatios 
(Supplemental File 1/Figures S5).
For all three gene list selection methods, pairs of genes in which either the protein-coding or the antisense was 
expressed in less than seven tumor samples or seven adjacent non-malignant samples were discarded.
Survival analysis. All protein-coding genes from the three gene lists have been tested for association with 
survival using an external dataset of 1066 RNA-Seq samples from the tumors of female breast cancer patients 
(Package R TCGA Biolinks33). Association with survival was recorded when the p-value of a log-rank test was less 
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than 0.05. The ratio of genes associated with survival in each list has been compared using the same ratio com-
puted with two control distributions (95% CI of 200 random pair distributions) of protein-coding genes: the first 
control contained protein-coding genes with no overlap with the antisense, while the second control contained 
protein-coding genes overlapping the antisense (i.e., protein-coding genes from previously defined 9632 pairs of 
protein-coding genes and antisense) but were not selected by the three analysis methods used.
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